Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386468 | 1.00 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL27228919 | 1.00 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL26906164 | 0.89 | CYP2D6 (0.32) | ALDH1A1MEN1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL1845464 | 0.89 | CYP2D6 (0.36) | ALDH1A1MEN1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL21760775 | 0.89 | CYP2D6 (0.36) | ALDH1A1MEN1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL1133701 | 0.89 | CYP2D6 (0.36) | ALDH1A1MEN1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL16720978 | 0.83 | CYP2D6 (0.45) | ALDH1A1MEN1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL16720982 | 0.83 | CYP2D6 (0.45) | ALDH1A1MEN1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL13612925 | 0.82 | NOS3 (0.32) | ALDH1A1MEN1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL22283565 | 0.82 | CYP3A4 (0.39) | ALDH1A1MEN1KMT2ACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689879-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-02-12 | — | — | EP | disclosed |
| US-11274101-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-11242348-B2 | — | — | 2022-02-08 | — | — | US | disclosed |
| US-20200255439-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-13 | — | — | US | disclosed |
| EP-3689879-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-8841334-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8546583-B2 | Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2222165-B1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255439-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | ALDH1A1 1193/4885MEN1 187/4885KMT2A 1637/4885 |
| US-11274101-B2 | Heterocyclic compound | MAG, HTT, ACHE | ALDH1A1 1193/4885MEN1 187/4885KMT2A 1637/4885 |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | ALDH1A1 898/4885MEN1 1534/4885KMT2A 1378/4885 |
| US-11242348-B2 | — | MAG, ACHE, GAP43 | ALDH1A1 1166/4885MEN1 505/4885KMT2A 1665/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | ALDH1A1 914/4885MEN1 1218/4885KMT2A 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.